FDA OKs Cabozantinib for Pancreatic Neuroendocrine Tumors

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-oks-cabozantinib-pancreatic-neuroendocrine-tumors-2025a10007bi?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost